Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;26(4):309-17.
doi: 10.1016/j.beha.2013.09.001. Epub 2013 Oct 1.

The evolving challenge of therapy-related myeloid neoplasms

Jane E Churpek  1 , Richard A Larson  2
Affiliations
Review

The evolving challenge of therapy-related myeloid neoplasms

Jane E Churpek et al. Best Pract Res Clin Haematol. 2013 Dec.

Abstract

Therapy-related myelodysplastic syndrome (t-MDS) and therapy-related acute myeloid leukemia (t-AML) are late complications of cytotoxic therapies used to treat malignant, and increasingly, non-malignant conditions. Although distinct clinical, morphologic, and genetic features can be recognized, these disorders should be seen as part of a single disease spectrum recognized by the WHO in a singular classification, therapy-related myeloid neoplasms (t-MNs). Etiologic factors for t-MNs remain elusive, but ongoing research has characterized risk factors which vary between patient subgroups and exposures. Agents that damage DNA directly, interfere with DNA repair, and suppress the immune system's ability to detect malignant cells increase the risk of t-MNs. As in primary MDS and de novo AML, prognosis and treatment strategies rely on patient characteristics as well as cytogenetics. However, the overall outcome for patients with t-MNs remains poor. Here we review our current understanding of t-MNs as they are most often encountered by the practicing clinician.

Keywords: leukemia; myelodysplastic syndrome; myeloid; neoplasm; therapy-related.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Treatment algorithm for individuals with therapy-related myeloid neoplasms.
See this image and copyright information in PMC

References

    1. Vardiman JW, Arber DA, Brunning RD, et al. Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth ed. Lyon, France: IARC Press; 2008. pp. 127–129.
    1. Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137–2145. - PubMed
    1. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102(1):43–52. - PubMed
    1. Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Internat J Hematol. 2000;71(2):144–152. - PubMed
    1. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35(4):418–429. - PMC - PubMed

Publication types

MeSH terms

Substances